Selected article for: "individual level and release inform"
Author: Emily R Adams; Rekha Anand; Monique I Andersson; Kathryn Auckland; J Kenneth Baillie; Eleanor Barnes; John Bell; Tamsin Berry; Sagida Bibi; Miles Carroll; Senthil Chinnakannan; Elizabeth Clutterbuck; Richard J Cornall; Derrick W Crook; Thushan De Silva; Wanwisa Dejnirattisai; Kate E Dingle; Christina Dold; David W Eyre; Helen Farmer; Sarah J Hoosdally; Alistair Hunter; Katie Jeffrey; Paul Klenerman; Julian Knight; Clarice Knowles; Andrew J Kwok; Ullrich Leuschner; Chang Liu; Cesar Lopez-Camacho; Philippa C Matthews; Hannah McGivern; Alexander J Mentzer; Jonathan Milton; Juthathip Mongkolsapaya; Shona C Moore; Marta S Oliveira; Fiona Pereira; Timothy Peto; Rutger J Ploeg; Andrew Pollard; Tessa Prince; David J Roberts; Justine K Rudkin; Gavin R Screaton; Malcolm G Semple; Donal T Skelly; Elliot Nathan Smith; Julie Staves; David Stuart; Piyada Supasa; Tomas Surik; Pat Tsang; Lance Turtle; A Sarah Walker; Beibei Wang; Charlotte Washington; Nicholas Watkins; James Whitehouse; Sally Beer; Robert Levin; Alexis Espinosa; Dominique Georgiou; Jose Carlos Martinez Garrido; Hannah Thraves; Elena Perez Lopez; Maria del Rocio Fernandez Mendoza; Alberto Jose Sobrino Diaz; Veronica Sanchez
Title: Evaluation of antibody testing for SARS-Cov-2 using ELISA and lateral flow immunoassays
  • Document date: 2020_4_20
    • ID: 5trox1i5_39
    Snippet: In summary, antibody testing is crucial to inform release from lockdown. This study offers insights into the performance of both a novel ELISA and a panel of LFIA devices that have been made widely available, but to date with limited systematic validation. Our findings suggest that while current LFIA devices may provide some information for population-level surveys, their performance is inadequate for most individual patient applications. The bio.....
    Document: In summary, antibody testing is crucial to inform release from lockdown. This study offers insights into the performance of both a novel ELISA and a panel of LFIA devices that have been made widely available, but to date with limited systematic validation. Our findings suggest that while current LFIA devices may provide some information for population-level surveys, their performance is inadequate for most individual patient applications. The biobank of samples assembled for this study continues to be expanded and will provide a valuable resource for developing the next generation of ELISA and lateral flow assays. The ELISA we . CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

    Search related documents:
    Co phrase search for related documents
    • antibody testing and lateral flow: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • antibody testing and lfia device: 1
    • antibody testing and population level: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17
    • international license and lateral flow: 1
    • international license and lockdown release: 1
    • international license and population level: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17
    • lateral flow and lfia device: 1, 2, 3
    • lateral flow and population level: 1, 2, 3, 4, 5, 6, 7, 8, 9
    • lfia device and population level: 1
    • lockdown release and population level: 1, 2
    • patient application and population level: 1, 2
    • population level and sample biobank: 1